We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Toolkit Developed for Iron Deficiency in Pregnancy

By LabMedica International staff writers
Posted on 04 Sep 2019
The risk of iron deficiency (ID) increases during pregnancy due to an increase in maternal iron requirements to accommodate the expansion of maternal red blood cell (RBC) mass, development of the placenta and fetus, and the loss of blood associated with labor and delivery.

Fortunately, early detection of ID and treatment with daily iron supplementation is a straightforward and effective method of addressing ID. More...
Iron deficiency and ID anemia (IDA) can be detected using simple blood tests of hemoglobin and ferritin, but often go unrecognized and untreated due to lack of knowledge of their implications and competing clinical priorities.

A team of scientists working with St. Michael’s Hospital (Toronto, ON, Canada) developed and implemented a novel quality-improvement toolkit: ID in pregnancy with maternal iron optimization (IRON MOM) at the hospital. The toolkit included clinical pathways for diagnosis and management, educational resources for clinicians and patients, templated laboratory requisitions, and standardized oral iron prescriptions.

To measure the effectiveness of the toolkit, the team included the rates of ferritin testing, and outcome measures of the proportion of women with an antenatal hemoglobin value below 100 g/L (anemia), the proportion of women who received a red blood cell (RBC) transfusion during pregnancy, and the proportion of women who received an RBC transfusion immediately following delivery or in the 8-week postpartum period.

The pre-intervention period was from January 2012 to December 2016, and the post-intervention period was from January 2017 to December 2017. From the electronic patient records (EPR), 1,292 and 2,400 ferritin tests and 16,603 and 3,282 antenatal hemoglobin results were extracted pre- and post-intervention, respectively. One year after implementation of IRON MOM, they found a 10-fold increase in the rate of ferritin testing in the obstetric clinics at the hospital and a lower risk of antenatal hemoglobin values below 100 g/L (pre-intervention 13.5%; post-intervention 10.6%). In addition, a significantly lower proportion of women received an RBC transfusion during their pregnancy (1.2% pre-intervention versus 0.8% post-intervention) or immediately following delivery and in the eight weeks following (2.3% pre-intervention versus 1.6% post-intervention).

The authors concluded that the introduction of a standardized toolkit including diagnostic and management pathways as well as other aids increased ferritin testing and decreased the incidence of anemia among women presenting for delivery at their site. This strategy also resulted in reduced proportions of women receiving RBC transfusion during pregnancy and in the first eight weeks postpartum. The IRON MOM toolkit is a low-tech strategy that could be easily scaled to other settings.

Related Links:
St. Michael’s Hospital


Gold Member
Troponin T QC
Troponin T Quality Control
Serological Pipet Controller
PIPETBOY GENIUS
New
Varicella Zoster Test
ZEUS ELISA Varicella Zoster IgG Test System
New
Enterovirus Test
Quanty Enterovirus System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The precision oncology test identifies patients most at risk of undergoing severe toxicity from treatment with 5FU/capecitabine (Photo courtesy of 123RF)

Precision Oncology Test Predicts Patient Toxicity Before Beginning Chemotherapy

5-fluorouracil (5FU) and capecitabine have been cornerstone chemotherapeutic agents for over four decades, effectively treating a variety of cancers. However, 5FU/capecitabine can cause varying degrees... Read more

Immunology

view channel
Image: Custom hardware and software for the real-time detection of immune cell biophysical signatures in NICU (Photo courtesy of Pediatric Research, DOI:10.1038/s41390-025-03952-y)

First-Of-Its-Kind Device Profiles Newborns' Immune Function Using Single Blood Drop

Premature infants are highly susceptible to severe and life-threatening conditions, such as sepsis and necrotizing enterocolitis (NEC). Newborn sepsis, which is a bloodstream infection occurring in the... Read more

Pathology

view channel
Image: Mimix Reference Standards are cell-line derived to maintain genomic complexity and mimic patient material across molecular diagnostics workflows (Photo courtesy of Revvity)

New Cancer Testing Standards to Improve Diagnostic Accuracy for Oncology Labs

Accurate diagnosis, including the identification of genomic markers, is essential for determining the most effective cancer treatments for patients. To ensure this, laboratories require reliable reference... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.